GERMANTOWN, Md., Oct. 28, 2019 /PRNewswire/ -- Neuralstem,
Inc. (NASDAQ:CUR), announces that the company has changed its name
to Seneca Biopharma, Inc. The company anticipates that its shares
will begin trading on the NASDAQ Capital Market under the symbol
SNCA on November 1, 2019 or shortly
thereafter subject to the satisfaction of customary conditions of
the exchange. Concurrently with the name change, Seneca has launched its new corporate website
at www.senecabio.com.
"The name change represents a new philosophy in our organization
as we move away from our prior emphasis on research related to
neurological disorders to a new focus which is geared towards
finding promising new science, developing a pipeline of
biopharmaceuticals and commercializing those products while at the
same time creating value for our stakeholders," commented Dr.
Ken Carter, executive chairman of
Seneca.
About Seneca Biopharma
Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical
company developing novel treatments for diseases of unmet medical
need. Seneca is in the process of
finding and acquiring new assets, promising sciences and
technologies that will provide meaningful therapies for
patients.
Cautionary Statement Regarding Forward Looking
Information
This news release contains "forward-looking statements" made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
relate to future, not past, events and may often be identified by
words such as "expect," "anticipate," "intend," "plan," "believe,"
"seek" or "will." Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific
risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking
statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical
trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of
our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
in Seneca Biopharma's periodic reports, including its Annual Report
on Form 10-K for the year ended December 31,
2018 as well as its subsequent quarterly reports on Form
10-Q, filed with the Securities and Exchange Commission (SEC). We
do not assume any obligation to update any forward-looking
statements.
Contact:
Josh Barer
Hibiscus BioVentures
josh@hibiscusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/neuralstem-becomes-seneca-biopharma-300946165.html
SOURCE Neuralstem, Inc.